ReviewCurrent medicinal chemistry2014
Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.
Review in Current medicinal chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 53 citations in OpenAlex.
- Bile acids as a "new hormone" in aging-related liver disease.Life medicine · 2026Review
- Dynamic Evolution of Bacterial Ligand Recognition by Formyl Peptide Receptors.Genome biology and evolution · 2023Article
- Mind the Gap-A Perspective on Strategies for Protecting against Bacterial Infections during the Period from Infection to Eradication.Microorganisms · 2023Review
- The Formyl Peptide Receptor 2 as a Target for Promotion of Resolution of Inflammation.Current neuropharmacology · 2023Article
- Developmental and homeostatic signaling transmitted by the G-protein coupled receptor FPR2.International immunopharmacology · 2023Review
- Neutrophil Immunomodulatory Activity of Nerolidol, a Major Component of Essential Oils fromPlants (Basel, Switzerland) · 2022Article
- Promiscuous Receptors and Neuroinflammation: The Formyl Peptide Class.Life (Basel, Switzerland) · 2022Review
- Structural basis for recognition of N-formyl peptides as pathogen-associated molecular patterns.Nature communications · 2022Article
- Neutrophil Immunomodulatory Activity of Farnesene, a Component ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Molecular recognition of formylpeptides and diverse agonists by the formylpeptide receptors FPR1 and FPR2.Nature communications · 2022Article
- Caulerpin MitigatesInternational journal of molecular sciences · 2021Article
- A network of core and subtype-specific gene expression programs in myositis.Acta neuropathologica · 2021Article
- Formyl peptide receptor 2, as an important target for ligands triggering the inflammatory response regulation: a link to brain pathology.Pharmacological reports : PR · 2021Review
- The Role of Formyl Peptide Receptors in Permanent and Low-Grade Inflammation:International journal of molecular sciences · 2021Review
- The effect of the WKYMVm peptide on promoting mBMSC secretion of exosomes to induce M2 macrophage polarization through the FPR2 pathway.Journal of orthopaedic surgery and research · 2021Article
- The Role of Formyl Peptide Receptors in Neurological Diseases via Regulating Inflammation.Frontiers in cellular neuroscience · 2021Review
- Changes of lipoxin levels during pregnancy and the monthly-cycle, condition the normal course of pregnancy or pathology.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2020Review
- AFrontiers in pharmacology · 2020Article
- The Contribution of Formyl Peptide Receptor Dysfunction to the Course of Neuroinflammation: A Potential Role in the Brain Pathology.Current neuropharmacology · 2020Review
- Aurantiamide-related dipeptide derivatives are formyl peptide receptor 1 antagonists.MedChemComm · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
Abstract
Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. These receptors play an important role in the regulation of inflammatory reactions and sensing cellular damage. They have also been implicated in the pathogenesis of various diseases, including neurodegenerative diseases, cataract formation, and atherogenesis. Thus, FPR ligands, both agonists and antagonists, may represent novel therapeutics for modulating host defense and innate immunity. A variety of molecules have been identified as receptor subtype-selective and mixed FPR agonists with potential therapeutic value during last decade. This review describes our efforts along with recent advances in the identification, optimization, biological evaluation, and structure-activity relationship (SAR) analysis of small molecule non-peptide FPR agonists and antagonists, including chiral molecules. Questions regarding the interaction at the molecular level of benzimidazoles, pyrazolones, pyridazin-3(2H)-ones, N-phenylureas and other derivatives with FPR1 and FPR2 are discussed. Application of computational models for virtual screening and design of FPR ligands is also considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.